Please login to the form below

NIH

This page shows the latest NIH news and features for those working in and with pharma, biotech and healthcare.

Moderna preparing for interim analysis of late-stage COVID-19 vaccine data

The study, which is being conducted in collaboration with the US National Institutes of Health (NIH), is investigating two shots of the candidate at a dosage of 100 µg.

Latest news

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

According to Reuters, a US National Institutes of Health (NIH) spokeswoman said the trial in question was paused when the independent data and safety monitoring board (DSMB) found that the
UK's MHRA begins rolling review of Moderna’s coronavirus vaccine

Moderna’s COVID-19 vaccine entered phase 3 in record time, with the US National Institutes of Health (NIH) partnered study launching in July.
Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

According to Reuters, a US National Institutes of Health (NIH) spokeswoman said the trial in question was paused when the independent data and safety monitoring board (DSMB) found that the
Moderna completes enrolment of phase 3 COVID-19 vaccine trial

Another 2, 000 participants are retail, restaurant and hospitality workers. Moderna’s COVID-19 vaccine entered phase 3 in record time, with the US National Institutes of Health (NIH) partnered study
Moderna’s chief exec expects to have COVID-19 vaccine data in November

The study, which is being conducted in collaboration with the US National Institutes of Health (NIH), is investigating two shots of the candidate at a dosage of 100 µg.

More from news
Approximately 7 fully matching, plus 82 partially matching documents found.

Latest Intelligence

Developing a COVID-19 vaccine

The phase 1 study, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle, aims to recruit 45 healthy men
As COVID-19 takes over the world, biopharma fights back

Lane is currently overseeing ongoing studies at the US National Institutes of Health (NIH), including its remdesivir study.
Driving the innovation engine

key. Cultural adoption is another goal. NIH (Not Invented Here) Syndrome is a fact of life in organisations large and small.
Streamlining clinical trials – why better data use is key

Today, CTTI is building on this work by collaborating with an NIH workgroup to develop a comprehensive plan for assessing the NIH’s sIRB policy, and by developing resources to assist
SEO for the healthcare industry

Frequently, the leader for UK searches is www.NHS.uk/conditions while www.webmd.com, www.cdc.gov, www.mayoclinic.org and http://www.ncbi.nlm.nih.gov/ are big hitters

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai has also previously served at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).
Sanofi names CSO Gary Nabel to Ebola role

Elias Zerhouni, president of Sanofi global research and development, said: “Given his past experience in public health epidemics as director of the NIH vaccine research centre and his leadership in developing ... an Ebola vaccine at NIH, Dr Nabel is
Former Pfizer exec Stephen Williams joins Venaxis board

run by the Foundation for NIH from 2005-2007.
Eric Green named NIH's data science lead

NIH). Dr Green takes the role on an interim basis while the NIH attempts to find someone to take on the position on a permanent basis to lead its efforts to ... Dr Green has been director of the NHGRI since 2009, having previously served as scientific
Sanofi appoints NIH’s Gary Nabel as chief scientific officer

Dr Gary Nabel has left US medical research centre the National Institutes of Health (NIH) to join Sanofi as senior VP, chief scientific officer and deputy to the president for global ... Dr Nabel leaves the NIH, which is part of the US government's

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Why Don't More People Want to Change the World?

Healthcare is critical. But healthcare will never be fixed to a point where we can say that it's done. Instead, it's about looking at things in new ways, exploring new ideas for changing behaviour to improve outcomes. For everyone. So, why don't
If our patients are diverse, why are clinical trials so white?

https://www.cdc.gov/cancer/skin/statistics/behavior/sunprotection. htm. https://www.ncbi.nlm.nih.gov/pubmed/15837865. https://www.sciencedirect.com/science/article/pii/ S0146280618301889. ... https://www.myeloma.org/diversity/how-myeloma-differentafrican-
Why we need to improve diverse representation in clinical trials

In the U.S., the National Institutes of Health (NIH) recently launched its“All of Us” research program, which is an historic effort to gather data from one million or more
Solaris Health looks at the gene therapy revolution

https://www.ncbi.nlm.nih.gov/books/NBK1483/ (accessed September 2018). 2.Evaluation consultation document – Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency.
Why patient education isn’t simple

www.ncbi.nlm.nih.gov/pubmed/23381513.

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Lead Copywriter: Competitive

Account Director – Creative Healthcare Communications: Competative

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...